Allotment Status
Registrar: Skyline Financial Services
Issue price
₹208
Listing price
₹395.2
Last GMP (₹)
₹70
GMP estimate
+33.65%
Actual listing gain
+90.00%
Return per lot
+₹1,12,320
GMP vs listing performance
GMP pointed to +33.65% but the stock listed at +90.00% — 56.3% higher than estimated.
Listing gain calculator
Estimate profit or loss based on actual listing performance
Based on issue price ₹208 × 600 shares per lot. Listing price ₹395. Excludes taxes, DP charges, and selling costs.
Listing results from exchange debut data where recorded. See GMP accuracy report · How we track this
Avience Biomedicals IPO listed on 25 Jun 2026 at an issue price of ₹208, gained 90.0% on listing day. It delivered strong listing returns for allottees. The issue was subscribed 385.24x overall.
Avience Biomedicals is a recently listed SME IPO in India, raising ₹30.24 Cr, with shares offered around ₹208. The stock has listed with a +90.0% debut move versus the issue price. As an SME issue, expect a larger lot size and thinner post-listing liquidity than a typical Mainboard IPO.
GMP and subscription figures are unofficial market data, refreshed twice daily for active IPOs. Last updated 22 Jun 2026, 05:43 pm IST. How we source data · Disclaimer
FAQ
Avience Biomedicals' shares listed at a 90% premium to the IPO price of ₹208, opening at ₹395.20 on the NSE SME. This strong listing indicates a positive market response to the company's debut. The stock's performance will be closely watched by investors in the coming days.
Read full story